2025 Fall
International Convention of PSK

D+7
October 22-24, 2025

Abstracts

P5-1

Logical exploration of cinnamoyl-containing nonribosomal peptides via metabologenomic targeting and regulator overexpression

  • Sangwook Kang1, Thanh-hau Huynh1, Jung min Kim1, Bo eun Heo2, Ben Shen3, Seung bum Kim4, Jichan Jang2, Sang kook Lee1, Yeo joon Yoon1, Dong-chan Oh*1
  • 1College of Pharmacy, Seoul National University, Republic of Korea
  • 2Division of Life Science, Gyeongsang National University, Republic of Korea
  • 3Department of Chemistry, Department of Molecular Medicine, and Natural Products Discovery Center, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, United States
  • 4Department of Microbiology and Molecular Biology, Chungnam National University, Republic of Korea

A targeted method for discovering cinnamoyl-containing nonribosomal peptides (CCNPs), a unique class of bioactive compounds, was devised using cinnamoyl isomerase, a key enzyme in the biosynthesis of the cinnamoyl moiety, as a genome mining probe. A total of 39 hit strains were obtained, including 35 from polymerase chain reaction-based screening of the in-house bacterial library (2.5% of 1,400 strains) targeting the cinnamoyl isomerase-encoding gene, and 4 from the genome mining of online databases. Sequence similarity networking and phylogenetic analyses of the isomerase amplicons (~530 bp) classified the CCNPs into three major substructure-based groups (Z-, E-, and M-type CCNPs) and revealed distinct clade-structure relationships (13 clades). To overcome the challenge of silent biosynthetic gene clusters, we activated these clusters by overexpressing conserved cluster-situated LuxR regulators combining with extensive culture optimization. CCNP production was metabolomically detected in the bacterial extracts using the characteristic UV absorption and MS/MS fragments of cinnamoyl moieties. CCNP production was observed in 20 of the 39 hit strains, resulting in the isolation of 6 new CCNPs, including oxy-skyllamycin B (2), gwanacinnamycin (3), and luxocinnamycins A–D (4–7), with high structural novelty. Their structures were elucidated using comprehensive spectroscopic analyses and multiple step chemical derivatizations and the putative biosynthetic pathways were bioinformatically proposed. Gwanacinnamycin (3) exhibited significant antimycobacterial activity, whereas luxocinnamycin A (4) displayed moderate antiproliferative activity against stomach cancer cells. Our findings highlight a targeted metabologenomic approach combined with transcriptional regulator overexpression as a logical and efficient platform for the discovery of bioactive compounds from nature.


Q&A

작성하기
  • There are no registered questions

Sponsored by